In a pivotal decision Friday, the Federal Circuit revived a key patent for Novartis' blockbuster heart failure drug Entresto, reversing a district court's earlier finding that the patent lacked sufficient written description. The ruling restores protections for U.S. Patent No. 8,101,659, which has been central to Novartis’ efforts to block generic versions of the $6 billion-per-year medication.

Federal Circuit: Patent Sufficiently Describes Invention

The three-judge appellate panel concluded that the patent provided an adequate written description, ensuring its validity. “The invention is plainly described throughout the specification,” the court stated, highlighting that the patent disclosed a pharmaceutical composition combining valsartan and sacubitril.

The panel also noted that even MSN Pharmaceuticals’ expert conceded the patent sufficiently described administering valsartan and sacubitril as a physical mixture.

In contrast to the district court’s 2023 ruling, which found that a skilled person could not have visualized the combination of the two active ingredients when the patent was filed in 2002, the appellate judges determined that the inventors clearly had possession of the claimed invention.

Ruling Comes Amid Multidistrict Litigation

The revived patent is part of ongoing multidistrict litigation where Novartis is fighting to stave off generic competition for Entresto, its best-selling drug. The U.S. Food and Drug Administration approved MSN Pharmaceuticals’ generic version on July 24, 2023, and the district court ruling that invalidated the Novartis patent was a significant win for the generics industry.

However, with the Federal Circuit’s reversal, Novartis regains a critical legal tool to defend its market position.

Patent Challenges: A Mixed Outcome

While the Federal Circuit restored the patent’s validity regarding its written description, it upheld the district court's earlier findings that the patent was not invalid due to obviousness, lack of enablement, or indefiniteness. These findings further solidified the patent’s strength moving forward.

Broader Implications

Entresto brought in $6 billion in 2023, underscoring its importance to Novartis’ portfolio. This ruling could delay the introduction of generics, preserving Novartis' exclusivity and market dominance for the drug.

For generic manufacturers like MSN Pharmaceuticals, the decision highlights the challenges of navigating patent litigation in the pharmaceutical industry, particularly in high-stakes cases involving blockbuster drugs.